

Speciation of *Candida* using chromogenic and cornmeal agar with determination of fluconazole sensitivity

Saroj Golia, K. Mallika Reddy*, K. Sujatha Karjigi and Vivek Hittinahalli

Department of Microbiology, Dr. B.R. Ambedkar Medical College, Kadugondanahalli, Bangalore-45
Karnataka, India

Abstract: *Objective and background:* Candidiasis is an important cause of fungal infections. This study was carried out to determine the species incidence using chrom agar & cornmeal agar, susceptibility pattern to fluconazole by microbroth dilution methods of yeasts isolated from the clinical samples. *Method:* Positive samples for candidiasis were collected from 112 patients at Dr B R AMC from April 2010 to April 2011, processed by routine methods, chrom agar media and corn meal agar was used to speciate and antifungal susceptibility done by microbroth dilution method. *Results;* *C.albicans*(40), *C.tropicalis*(30), *C.parapsilosis* (22), *C.krusei* (5), *C glabrata*(15) were obtained. Susceptibility to fluconazole showed MIC *C.albicans* (0.125-0.5ug/ml), *C.tropicalis* (0.5-2ug/ml), *C.parapsilosis* (0.5-4 ug/ml), *C.glabrata* (16-32ug/ml) *C.krusei* (32-64ug/ml), *Conclusion:* Increasing incidence of non albicans species infection. The MIC of non albicans also showed increased values.

Keywords: *Candida*, Chrom agar, cornmeal agar, fluconazole

Introduction

Infections due to *Candida* species are increasing as the number of immunocompromised patients are increasing, undue usage of antibiotics, and cancer patients are more susceptible to fungal infections. Identification of *Candida* to species level is definitely warranted as there is increase in the incidence of *Candida non albicans* infections [1]. The antifungal susceptibility of fluconazole has changed against the *Candida* species, *Candida non albicans* are being more resistant to fluconazole [2]. Since molecular techniques are too expensive using of Chrom agar for species differentiation would be of benefit for easy and rapid speciation [3-4]. The study helps to determine the non albican species and their increased MIC levels to fluconazole in the setup.

Material and Methods

It is a prospective study conducted at Dr B R AMC from 2010 April to 2011 April. The inclusion criteria were from patients having symptoms of candidiasis where other causes were ruled out. Samples first obtained where Gram stained, inoculated on to the SDA agar slopes (Sabouraud dextrose agar) incubated at 37⁰c for 24 hrs. Germ tube test was done and further were classified as albicans and non albicans. The germ

tube positive was further incubated at 45⁰c to look for the growth. They were also inoculated on to Chrom agar(hi media) from the SDA slopes, identification was made by colour and morphology of the colonies as per the manufacturer's instructions table 1 represents the colours produced by various species fig 1 shows the type and colour of the colonies on Chromagar after incubation at 37⁰c. Simultaneously the *Candida* strains were inoculated on to corn meal agar (CMA) for chlamyospore, blastoconidia formation and arrangement slide cultures fig 2 shows morphology on CMA, table 2 represents kind and pattern of chlamyospore & blastoconidia formation. Flow chart 1 represents the method followed for identification

	Name	Colour on chrom agar
A	<i>C albicans</i>	Light green
B	<i>C tropicalis</i>	Dark blue
C	<i>C parapsilosis</i>	Pale cream colour
D	<i>C glabrata</i>	pink
E	<i>C krusei</i>	Pale pink with white edge rough and spreading

Table-2: Type and arrangement of blastoconidia & chlamyospore formation		
	Name	Type and arrangement of blastoconidia & chlamyospore formation
A	<i>C albicans</i>	large, thick-walled chlamyospore, usually terminal and present singly or in small clusters along with clusters of round blastoconidia.
B	<i>C tropicalis</i>	oval blastoconidia singly or in small groups all along , long pseudohyphae.
C	<i>C parapsilosis</i>	short, pencil-like pseudohyphae with blastoconidia arranged singly along pseudohyphae
D	<i>Ckrusei</i>	yeast cells only
E	<i>C glabrata</i>	pseudohyphae with blastoconidia forming cross-matchstick appearance.




Fig-1: *Candida* speciation on Chromogenic agar





Fig-2: Type and arrangement of blastoconidia & chlamyospore formation



Inocula were prepared from 1-3 days old cultures on SDA. Suspensions were adjusted by using 0.5 McFarland standard. Antifungal susceptibility testing was carried out by microbroth dilution method as per CLSI guidelines M27-A2. Serial dilution of fluconazole was done (0.125,0.25,0.5,1,2,4,8,16, 32,64)ug/ml.[5] Sterile microdilution plates (96-u-shaped wells) were used. Rows 1-10 contained the series of drug dilutions in 100 ul volumes starting with the concentration of 0.125 ug/ml. 100 ul of inoculum suspension were added to each well. The eleventh well was the control well, 100 ul of inoculum suspension and 100 ul of drug free medium were added. The plates were covered, incubated at room temperature and examined after 48, 72 hours incubation [5-6] Break points isolates of MIC Isolates with MIC < 8 ug/ml were considered to be susceptible to fluconazole, whereas isolates with MIC > 64 ug/ml were considered to be resistant. Isolates with MICs between 16-32 ug/ml were fluconazole susceptible-dose dependant (S-DD) [6-7].

Results

A total 112 patient positive of *Candida* species were collected the goal of the study was to show there is increase in the incidence of *Candida non albicans*. Table 3 shows the number and species of candida (chart 2represents table 3) *C. albicans* (35.7%) was the most common species among the isolates. Other *Candida* species isolated were, *C. tropicalis*(26.7%), *C. parapsilosis*(19.6%), *Candida glabrata*(13.6%), and *C. krusei* (4.4%) Thus, the overall prevalence of non-albicans candida species was per cent (72/112)64.2%. There was increase in MIC levels against the levels of fluconazole,

Candida albicans showed the lowest MIC levels while *C krusei* showed highest MIC values table 4 shows MIC of all species and MIC 90 was also done. Chart 3 represents table 4.

Chart-2: Candida species distribution





Table-3: Distribution of Candida species

Name	Number	Percentage
<i>C.albicans</i>	40	36%
<i>C.tropicalis</i>	30	27%
<i>C.parapsilosis</i>	22	20%
<i>C.glabrata</i>	15	13%
<i>C.krusei</i>	5	4%
Total	112	100

Table-4: MIC distribution to fluconazole

Name	MIC Range (ug/ml)	MIC 90 (ug/ml)
<i>C. albicans</i>	0.125-0.5	0.25
<i>C. tropicalis</i>	0.5-2	2
<i>C. parapsilosis</i>	0.5-4	2
<i>C. glabrata</i>	16-32	32
<i>C.krusei</i>	32-64	64

Chart-3: MIC distribution of Candida species to fluconazole



Discussion

The potential clinical importance of species-level identification has been recognized as *Candida* species differ in the expression of virulence factors and antifungal susceptibility [3-4]. Infections with these yeast species also have a direct impact on the choice of empiric antifungal therapy and clinical outcome. The potential clinical importance of species-level identification has been recognized as *Candida* species differ in the antifungal susceptibility [3-4]. Chromogenic medium was able to identify *Candida albicans*, *C. tropicalis*, *C. krusei*, *C. parapsilosis*. Chromogenic medium was also helpful in identifying "multi-species" yeast infections [3, 8-10]. Antifungal choice is first based on *Candida* species identification, but antifungal susceptibility testing will play an increasingly

important role when selecting antifungal drug dosage to use. Standardized methods for antifungal susceptibility testing have been available for many years. The Clinical and Laboratory Standards Institute (CLSI) standardized broth microdilution method remains a reference for antifungal susceptibility testing. Indeed, clinically relevant interpretative breakpoints are available and quality control strains are validated. Nevertheless for the CLSI method, serial twofold dilutions ranging from 0.125 to 64 ug/ml for fluconazole [6-7,10] thus the present study shows using Chromagar & cornmeal agar helps us to speciate with ease, shows that increasing incidence of *Candida non albicans*. MIC levels also helps to determine the dosage pattern of each species.

References

- Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. *BMC Infect Dis* 2010; 10:150.
- Bourgeois N, Dehandschoewercker L, Bertout S, Bousquet PJ, Rispail P and Lachaud L. Antifungal susceptibility of 205 *Candida* spp. Isolated primarily during Invasive candidiasis and comparison of the vitek 2 system with the CLSI broth microdilution and test methods. *J of clinical microbiology*, 2010; 154-161.
- Murray MP, Zinchuk R, Larone DH. CHROMagar *Candida* as the sole primary medium for isolation of yeasts and as a source medium for the rapid-assimilation-of-trehalose test. *J Clin Microbiol* 2005; 43:1210-2.
- Amina Mostafa Abdel Aal, Mohamed M. Taha, Noha El-Mashad and Walaa El-Shabrawy. Antifungal susceptibility testing: *New trends Egyptian dermatology online journal* 2007; 3(1):1.
- Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. Wayne, PA: *Clinical Laboratory Standards Institute*; 2002.
- Hoffman HL and Pfaller MA. In vitro antifungal susceptibility testing. *Pharmacotherapy* 2001; 21(8pt2):1115-1235.
- Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al. Bloodstream infections due to *Candida* species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. *Antimicrobial Agents Chemotherapy* 2000;44:747-51.
- Lynn L. H., Duane R. H., Elirion K. M. Dooley D. Direct isolation of candida spp from blood cultures on the chromogenic medium CHROM agar candida. *J Clin Microbiol.* 2003; 41(6):2629-2632.
- Venitia M. Cooke L, Miles RJ, Price RG, Midgley G, Khamri W, and Richardson C. New Chromogenic Agar Medium for the Identification of *Candida* spp. *Applied and environmental microbiology*, 2002; 3622-3627.
- Agarwal S, Manchanda V, Verma N, Bhalla P. Yeast identification in routine clinical microbiology laboratory and its clinical relevance. *Indian J Med Microbiology* [serial online] 2011 [cited 2012 May 5]; 29:172-7.

*All correspondences to: Dr. K. Mallika Reddy, No 24, 1st Cross Bhuvanappa Layout, DR College, Post Hosur Main Road, Bangalore-560029 Karnataka, India. Email: shrin_reddy@yahoo.co.in